Clinical trial · Observational
Patient-derived Organoids of Lung Cancer to Test Drug Response
NCT03979170CI-TRIAL-00077661recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a single center, single arm, open and exploratory clinical study, with 50 cases planned for a period of 3 years. The purpose of this study is to evaluate the consistency and accuracy of a Patient-Derived Organoid (PDO) Model of lung cancer to predict the clinical efficacy of anti-cancer drugs, in order to predict the best chemotherapy regimen for each given patient.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Organoid | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lung tumor resection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Patient-derived organoid establishment
- timeFrame
- 3 years
- description
- Successful generation of lung cancer organoids (growth of lung tumoral cells). The rate of successful generation of lung cancer organoids could vary with the age of the patient, the histological and molecular subtype of lung cancer
- measure
- Patient-derived organoid validation
- timeFrame
- 5 years
- description
- Proportion of patient-derived organoids that are histologically and genetically identical to the source tumour
Secondary outcomes (2)
- measure
- Drug sensitivity
- timeFrame
- 2019 - 2023
- description
- Drug sensitivity of patient-derived tumour organoids (drug screening and chemotherapy resistance test) Secondary drug effects on patient-derived normal lung organoids
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically proven lung cancer * Age ≥ 18 * Written informed and signed consent * Accessible to biopsy and/or surgery sample of metastasis and/or primitive tumour Exclusion Criteria: * Less than 18 years of age * Not able to give informed consent (language, intellectual capacities, etc.) * Not accessible to biopsy and/or surgery sample * Not enough lung tissue for a histological analysis or the remaining lung tissue is not enough to perform a routine pathological analysis.
References
Publications (1)
- BACKGROUNDMueggler A, Pilotto E, Perriraz-Mayer N, Jiang S, Addeo A, Bedat B, Karenovics W, Triponez F, Serre-Beinier V. An Optimized Method to Culture Human Primary Lung Tumor Cell Spheroids. Cancers (Basel). 2023 Nov 25;15(23):5576. doi: 10.3390/cancers15235576. PMID 38067281